Followers | 608 |
Posts | 42247 |
Boards Moderated | 6 |
Alias Born | 01/10/2004 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Sunday, September 12, 2010 11:52:06 PM
TRDX Announces Completion of Key Milestone and Provides Details on Closing of Definitive Agreement With Genesis Biopharma, Inc.
Friday , September 10, 2010 16:30ET
http://www.knobias.com/story.htm?eid=3.1.f8e2d67505bd21745d8bcb98830cfb17f362430e3ae9f774836592c8555fadb8
http://www.knobias.com/individual/public/quote.htm?ticker=TRDX
http://www.otcmarkets.com/stock/TRDX/company-info
http://www.barchart.com/detailedquote/stocks/TRDX
http://www.genesisbiopharma.com/newsandevents.html
JERICHO, NY -- (Marketwire) -- 09/10/10 -- SciMeDent Health, Corp. f/k/a Trend Exploration, Inc. ("TRDX" or the "Company") (PINKSHEETS: TRDX) today confirms it has completed the structuring of DiabetRX Pharma Corp. ("DiabetRX") which will be assigned the Sublicense and upon Final Closing will be 100% owned by TRDX.
In addition, the Company provides the following details regarding the recently executed Definitive Sublicense Agreement ("Definitive") with Montreal-based Genesis Biopharma, Inc. ("Genesis").
General Terms:
Financing TRDX has committed to a financing of $800,000 for the
continued R&D of Genesis' Painful Diabetic Neurapathy
("PDN") solution
The financing can be completed in tranches, with each
tranche resulting in a pro-rated ownership of DiabetRX.
First Tranche $60,000 required to maintain sublicense and take possession
of the first 7.5% of DiabetRX
Initial Closing The Initial Closing is based on, amongst other items, the
completion of customary due diligence by the parties
Final Closing Final Closing is defined as the completion of the $800,000
financing for the development of the PDN solution
Dr. Jan Stahl, CEO of TRDX, commented: "Since the signing of the Definitive Agreement, I am very happy with the progress we have made with Genesis. We feel confident in the current steps we are taking to complete the Initial Closing and first Tranche financing. We view DiabetRX as a long term investment with large potential and look forward to the Final Closing."
About Genesis Biopharma, Inc.
Genesis Biopharma, Inc. (http://www.genesisbiopharma.com) is a Canadian corporation founded in 2007 to exploit the commercial potential for the therapeutic use of peptidomimetic (modified amino acid peptides) compounds. Amino acids are the building blocks of proteins, which are found in every cell. Proteins consist of extremely long and complex amino acid chains. In contrast, a peptide is a short string of amino acids, joined by chemical bonds (also called "amide bonds").
About SCIMEDENT f/k/a Trend Exploration, Inc. (PINKSHEETS: TRDX)
SciMeDent is a company focused on being a leading developer and marketer of products and services for medicine, dentistry and life sciences. SciMeDent plans to achieve growth initially through mergers and acquisitions.
Cautionary Statement Regarding Forward-Looking Statements
A number of statements contained in this press release are forward-looking statements. These forward-looking statements involve a number of risks and uncertainties, including the sufficiency of existing capital resources, technological or industry changes and uncertainties related to the development of the Company's business model. The actual results the Company may achieve could differ materially from any forward-looking statements due to such risks and uncertainties.
Contact:
SciMeDent Health Corp. f/k/a Trend Exploration, Inc.
dmyers@cadenceconsultingllc.com
1-866-383-1374
Source: Trend Exploration, Inc.
Public Companies Associated with this story:
TRDX
Knobias Subject Codes Associated with this story:
Corp Financing Important Co. News Major Agreements Management Issues
Merger/Acquisition Patent/Trademark Product News Regulators
Shareholder Issues
Content provided by Market Wire Copyright © 2010
Content transmitted by Knobias.com Copyright © 2010 Visit Knobias.com
http://www.knobias.com/story.htm?eid=3.1.f8e2d67505bd21745d8bcb98830cfb17f362430e3ae9f774836592c8555fadb8
http://www.knobias.com/individual/public/quote.htm?ticker=TRDX
http://www.otcmarkets.com/stock/TRDX/company-info
http://www.barchart.com/detailedquote/stocks/TRDX
http://www.genesisbiopharma.com/newsandevents.html
ABOUT | PARTNERS | ADVERTISING INFO | CONTACT US | COPYRIGHT | PRIVACY | LEGAL | DISCLAIMER
Copyright © 2010 Knobias.Com, LLC. All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Knobias.Com, LLC, nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Knobias.Com website(s), a user agrees not to redistribute the information found therein. Knobias.Com, LLC is not a registered broker-dealer and does not endorse or recommend any securities listed herein or any services of any brokerage company.
Stop By And Visit Me At The SmallCap Trading Techniques Board
http://investorshub.advfn.com/boards/board.aspx?board_id=4203
Valuable Trading Ideas to help you make more MOMO!
http://investorshub.advfn.com/boards/board.aspx?board_id=4203
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM